Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2020-10-20 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于公司2019年限制性股票激励计划回购价格、数量调整及回购注销部分限制性股票的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2019 restricted stock incentive plan of a company. It discusses the repurchase price, quantity adjustments, and cancellation of some restricted stocks. The document is not a financial report, earnings release, or regulatory filing about financial results. It is a legal opinion related to stock incentive plan adjustments and repurchases, which does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is also not a simple announcement or certification but a detailed legal opinion letter. The closest fitting category is Regulatory Filings (RNS) as it is a legal document related to compliance and corporate governance matters that do not fit other specific categories.
2020-10-20 Chinese
关于回购注销2019年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding the repurchase and cancellation of restricted stock under the company's 2019 restricted stock incentive plan. It includes information about the approval procedures, reasons for repurchase, prices, quantities, funding sources, impact on shareholding structure, and opinions from independent directors, the supervisory board, and legal counsel. The content focuses on share repurchase related to stock incentives, not on financial results, management changes, or general regulatory filings. The document length is 4207 characters, which is relatively short but contains substantive details about the repurchase transaction itself, not just an announcement of a report. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2020-10-20 Chinese
2020年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 Third Quarter Report" of 厦门艾德生物医药科技股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2020. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is not a mere announcement or certification. The content matches the definition of an Interim / Quarterly Report (IR), which includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. 9M 2020
2020-10-20 Chinese
关于特定股东股份减持计划的预披露公告
Transaction in Own Shares Classification · 100% confidence The document is a pre-disclosure announcement regarding the planned reduction of shareholdings by specific shareholders of the company. It details the shareholders involved, the number and percentage of shares to be reduced, the methods and timing of the reduction, and related commitments and risk warnings. There is no financial data, earnings information, or report content. The document is an announcement about a shareholder's planned share reduction, which fits the category of Transaction in Own Shares (POS). The document length is 3423 characters, which is consistent with an announcement rather than a full report.
2020-10-13 Chinese
关于特定股东股份减持计划时间届满并拟继续减持公司股份的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a specific shareholder's plan to reduce their shareholding in the company, including details about the shares reduced, the schedule, and the shareholder's commitments. It discusses the completion of a previous share reduction plan and the intention to continue reducing shares. The content focuses on shareholding changes by a particular shareholder and the regulatory compliance of such actions. There is no financial report, earnings data, or management discussion. The document fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2020-09-29 Chinese
关于特定股东股份减持计划时间届满的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a specific shareholder's stock reduction plan, detailing the number of shares reduced, the time periods, prices, and compliance with relevant regulations. It includes tables showing shareholding before and after the reduction and confirms no violation of laws or company governance. There is no financial report, earnings data, or management discussion. The document focuses on shareholding changes by a major shareholder, specifically OrbiMed Asia Partners II, L.P. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2020-09-08 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.